Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter.

Perrigo (Nasdaq: PRGO;TASE) announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the Detroit Office of the Food and Drug Administration (FDA) has arrived at their Allegan facility for the re-inspection (see also U.S. Food and Drug Administration).

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Keywords: FDA, Perrigo, Pharmaceutical Company, Regulatory Actions, U.S. Food and Drug Administration.

This article was prepared by Biotech Week editors from staff and other reports. Copyright 2011, Biotech Week via NewsRx.com.